

Note : This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

## Question-and-Answer Session

Results Briefing for the 1H of the Fiscal Year Ending December 31, 2025

Outline of briefing session

16:30-17:30 on Friday, August 8, 2025 (Zoom webinar)

For institutional investors and analysts

**Question 1.** What factors contributed to the better-than-expected operating income in the first half of the year?

**Answer** This was mainly due to strong shipments of the CZ series and lower-than-expected use of SG&A expenses. A portion of the SG&A expenses are expected to be incurred in the second half due to postponed accounting.

**Question 2.** What is the status of state-of-the-art products and future prospects?

**Answer** Our state-of-the-art products are used by all of our major customers. We expect to be able to generate net sales while gradually accelerating our pace.

**Question 3.** Could you discuss net sales of chemicals in the second quarter?

**Answer** Our mainstay CZ-8101 showed steady growth. Other products in the CZ Series are growing steadily as well. Behind this, we believe, are generative AI-related devices, PCs, smartphones, and general-purpose servers, the last of which are getting better little by little despite a somewhat slow recovery. By region, smartphones are booming in China, and Taiwan is also on the road to recovery. In South Korea, there are also moves to transfer some general-purpose memory to China. However, we believe that shipments of new types of memory will also begin, and that we can hold high expectations for the future.

**Question 4.** Could you discuss new fields (interposers and high-frequency substrates)?

**Answer** We expect to start generating net sales around 2027, and seek to grow them as we head towards 2030.